Graham Paterson Buys 11,643 Shares of Diaceutics PLC (LON:DXRX) Stock

Diaceutics PLC (LON:DXRX) insider Graham Paterson purchased 11,643 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was bought at an average cost of GBX 138 ($1.70) per share, for a total transaction of £16,067.34 ($19,741.17).

Diaceutics Stock Performance

Diaceutics stock opened at GBX 136.25 ($1.67) on Monday. The company has a debt-to-equity ratio of 2.93, a current ratio of 4.85 and a quick ratio of 9.92. Diaceutics PLC has a 12 month low of GBX 92.24 ($1.13) and a 12 month high of GBX 151 ($1.86). The company has a fifty day moving average price of GBX 130.24 and a two-hundred day moving average price of GBX 128.62. The company has a market cap of £115.09 million, a PE ratio of -4,541.67 and a beta of 0.58.

Analyst Ratings Changes

Several research firms have recently weighed in on DXRX. Canaccord Genuity Group reissued a “buy” rating and issued a GBX 160 ($1.97) target price on shares of Diaceutics in a research report on Tuesday, December 17th. Canaccord Genuity Group restated a “buy” rating and set a GBX 160 ($1.97) price objective on shares of Diaceutics in a research note on Tuesday, December 17th.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.